Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
2017 · New England Journal of Medicine · 2,174 citations
https://doi.org/10.1056/nejmoa1709030
P
Paola Queirolo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
596
Papers
18.7K
Citations
68
h-index
209
i10-index
Paola Queirolo is an academic researcher from Martin University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Melanoma and MAPK Pathways & Cutaneous Melanoma Detection and Management. The author has an h-index of 68, co-authored 507 publications.
ORCID: 0000-0002-9917-6633Papers by this author
worksBinimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
2017 · The Lancet Oncology · 482 citations
https://doi.org/10.1016/s1470-2045(17)30180-8
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
2024 · New England Journal of Medicine · 378 citations
https://doi.org/10.1056/nejmoa2407417
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma
2014 · Nature Genetics · 322 citations
https://doi.org/10.1038/ng.2941
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
2020 · Nature Genetics · 230 citations
https://doi.org/10.1038/s41588-020-0611-8
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
2023 · Clinical Cancer Research · 162 citations
https://doi.org/10.1158/1078-0432.ccr-22-3145
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat